Study of Efficacy of PEAR-004 in Schizophrenia
Completed · Phase 2 · Has a placebo group
Conditions studied: Schizophrenia
In brief
The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS). The overall rationale for the study was to assess the first prescription digital therapeutic (PDT) in schizophrenia using a form of proven psychosocial intervention, cognitive behavioral therapy (CBT), to supplement standard of care with antipsychotic medications.
Key facts
- Study ID
- NCT03751280
- Run by
- Novartis Pharmaceuticals
- People needed
- 112
- Starts
- 2018-12-10
- Expected to finish
- 2019-09-26
- Last updated by the study team
- 2021-01-05
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Garden Grove, California, United States
- Novartis Investigative Site — Oakland, California, United States
- Novartis Investigative Site — Torrance, California, United States
- Novartis Investigative Site — Maitland, Florida, United States
- Novartis Investigative Site — Grand Rapids, Michigan, United States
- Novartis Investigative Site — Albuquerque, New Mexico, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.